Treatment
Octreotide clinical trials
We’re tracking 15 recruiting studies that include Octreotide, each written for real people, not researchers, below.
Recruiting studies
- NCT07583563Recruiting
Observational study of octreotide depot injections for acromegaly
This study watches how patients with acromegaly respond to octreotide, a medication given as injections under the skin. Researchers will collect information about how well the treatment works and any side effects you experience.
AachenAges 18 years+ - NCT05884255RecruitingPhase 3
Lutetium brain-sparing therapy for advanced gut and pancreas tumors
This Phase 3 trial tests lutetium (Lu-177) oxodotreotide, a targeted treatment, for people with advanced gut and pancreas neuroendocrine tumors that are low or medium grade (G1 or G2). The study will see whether it helps control the cancer and symptoms in the right patients.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05749289RecruitingPhase 2/Phase 3
PET/CT scan for tumors with positive SSTR signals
This trial looks at how a special PET/CT scan using a substance called Al18F-octreotide can find and evaluate tumors that show a certain target signal (SSTR). It may help doctors better see where the tumor is and guide next steps in care.
Beijing, Chao YangAges 18 years+ - NCT07165886RecruitingPhase 2/Phase 3
Study of sirolimus and octreotide for advanced neuroendocrine tumors
This trial tests a combination of two drugs, sirolimus and octreotide, for people with advanced neuroendocrine tumors in the digestive system that cannot be removed by surgery and are not making excess hormones. The goal is to see if this combination can help control the tumors.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07255248RecruitingPhase 4
Knee fat pad pain study for young female athletes
This study tests a treatment for knee fat pad pain in teenage girls who play organized sports. It aims to see if a specific injection helps after physical therapy hasn't worked.
Norwood, MassachusettsAges 12–18 - NCT06505395RecruitingPhase 2
Octreotide injection for advanced neuroendocrine tumors
This trial is testing an injectable medicine called octreotide for people with advanced neuroendocrine tumors of the digestive system or pancreas. It aims to see if the medicine can help control the tumor.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07057622RecruitingPhase 3
Comparing a new radiation therapy and long-acting medication for neuroendocrine tumors
This phase 3 trial tests a radioactive drug (177Lu-DOTATATE) against a long-acting medication (Octreotide LAR) for people with advanced neuroendocrine tumors (NETs) that have grown despite standard treatment. The study aims to see which treatment works better and is safer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04917484RecruitingPhase 2
Higher-precision PRRT dosing versus standard dosing for NEN
This Phase 2 study compares a more personalized (precision) radiation dose plan to the standard dose plan using Lu-177-DOTATOC for people with neuroendocrine neoplasms (NEN) that have worsened or caused major symptoms despite usual treatments. The goal is to see if better planning can improve treatment delivery while staying safe.
Aarhus, Palle Juul-Jensens BoulevardAges 18 years+ - NCT05477576RecruitingPhase 3
Lu-177–treated NET patients: new drug versus standard care
This Phase 3 trial tests RYZ101 versus standard of care in people with inoperable, well-differentiated SSTR-positive GI or pancreas neuroendocrine tumors (NETs) that keep growing after Lu-177 SSA. It may help by improving tumor control after your prior targeted radiation treatment.
Phoenix, ArizonaAges 18 years+ - NCT06592261RecruitingPhase 1
Insulin suppression test for weight groups
This study tests a new way to measure how the body handles insulin in people with different body weights. It may help researchers understand insulin resistance better.
New York, New YorkAges 18–65 - NCT06784752RecruitingPhase 3
Testing a targeted radiation therapy for advanced neuroendocrine tumors
This trial tests a radioactive drug called [177Lu]Lu-DOTA-TATE for people with advanced neuroendocrine tumors (GEP-NET) that have grown or spread. The drug targets tumor cells that have a specific receptor (SSTR) and delivers radiation directly to them, aiming to slow or shrink the tumors while limiting damage to healthy tissue.
Scottsdale, ArizonaAges 12–100 - NCT06878664RecruitingPhase 3
Lu177-Dotatate vs standard care for slow-growing midgut neuroendocrine tumors
This trial tests whether a radioactive drug called Lu177-Dotatate (PRRT) works better than usual care for people with slow-growing, advanced midgut neuroendocrine tumors (NETs). It may help shrink or slow the growth of tumors when you also get somatostatin analog therapy.
Caen, CaenAges 18 years+ - NCT07104487RecruitingPhase 2
PET/MRI scan to detect inflammation in carotid artery disease
This study tests whether a special type of PET/MRI scan can help doctors see inflammation in the carotid artery after a stroke or mini-stroke. By using a radioactive tracer, the scan may identify which patients have dangerous plaque buildup that could lead to another stroke.
Leuven, Vlaams-BrabantAges 18 years+ - NCT07262957RecruitingPhase 4
Preventing complications after pancreatic surgery with a drug bundle
This trial tests whether giving a combination of three treatments—hydrocortisone (a steroid), octreotide (a drug that reduces digestive fluids), and a tissue patch—before and during pancreatic surgery can help prevent complications. It is for people with a very small pancreatic duct (3 mm or less) who are scheduled for pancreatic surgery.
AmsterdamAges 18 years+ - NCT02019706RecruitingPhase 2
PET/CT scans to find the cause of ectopic Cushing syndrome
This trial tests several special imaging scans to help doctors locate the source of hormone overproduction in ectopic Cushing syndrome. It may help confirm where the problem is so treatment can be better targeted.
Bethesda, MarylandAges 18–80
What Octreotide is being studied for
Conditions with recruiting Octreotide studies.
Common questions
- Are there clinical trials studying Octreotide?
- Yes. Clin2 currently lists 15 recruiting studies that include Octreotide, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Octreotide trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Octreotide an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Octreotide or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.